Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 7 (July)

1. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
   J Clin Oncol, 25(19): 2811-8. [Abstract] [Full-text]
2. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
   J Clin Oncol, 25(19): 2792-7. [Abstract] [Full-text]
3. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
   BMC Med Genet, 8: 32. [Abstract] [Full-text]
4. GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells.
   J Cell Physiol, 212(3): 771-9. [Abstract] [Full-text]
5. Management of ovarian stromal cell tumors.
   J Clin Oncol, 25(20): 2944-51. [Abstract] [Full-text]
6. Management of ovarian germ cell tumors.
   J Clin Oncol, 25(20): 2938-43. [Abstract] [Full-text]
7. Management of borderline ovarian neoplasms.
   J Clin Oncol, 25(20): 2928-37. [Abstract] [Full-text]
8. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
   J Clin Oncol, 25(20): 2921-7. [Abstract] [Full-text]
9. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.
   J Clin Oncol, 25(20): 2909-20. [Abstract] [Full-text]
10. Experience with bevacizumab in the management of epithelial ovarian cancer.
    J Clin Oncol, 25(20): 2902-8. [Abstract] [Full-text]
11. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
    J Clin Oncol, 25(20): 2894-901. [Abstract] [Full-text]
12. Immunologic approaches to ovarian cancer treatment.
    J Clin Oncol, 25(20): 2884-93. [Abstract] [Full-text]
13. Role of surgery in ovarian carcinoma.
    J Clin Oncol, 25(20): 2873-83. [Abstract] [Full-text]
14. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
    J Clin Oncol, 25(20): 2867-72. [Abstract] [Full-text]
15. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
    Cancer Res, 67(13): 6351-9. [Abstract] [Full-text]
16. Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
    Cancer Res, 67(13): 6100-5. [Abstract] [Full-text]
17. Spontaneous resolution of acquired factor V inhibitor associated with ovarian carcinoma.
    Int J Lab Hematol, 29(4): 316-9. [Abstract] [Full-text]
18. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Nucl Med Commun, 28(8): 589-95. [Abstract] [Full-text]
19. Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
    Biochem Biophys Res Commun, 360(2): 363-9. [Abstract] [Full-text]
20. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
    J Histochem Cytochem, 55(8): 867-75. [Abstract] [Full-text]
21. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families.
    BMC Med Genet, 8: 40. [Abstract] [Full-text]
22. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Oncogene, 26(34): 4969-78. [Abstract] [Full-text]
23. Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.
    Oncogene, 26(34): 4961-8. [Abstract] [Full-text]
24. The outcomes of 27,063 women with unstaged endometrioid uterine cancer.
    Gynecol Oncol, 106(2): 282-8. [Abstract] [Full-text]
25. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Gynecol Oncol, 106(2): 318-24. [Abstract] [Full-text]
26. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
    Gynecol Oncol, 106(2): 305-10. [Abstract] [Full-text]
27. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
    Gynecol Oncol, 106(2): 311-7. [Abstract] [Full-text]
28. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
    Gynecol Oncol, 106(2): 381-7. [Abstract] [Full-text]
29. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Gynecol Oncol, 106(2): 354-61. [Abstract] [Full-text]
30. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
    Gynecol Oncol, 106(2): 342-7. [Abstract] [Full-text]
31. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Gynecol Oncol, 106(2): 334-41. [Abstract] [Full-text]
32. Unusual cause of painful shoulder in an elderly woman with rheumatoid arthritis.
    Clin Rheumatol, 26(9): 1549-51. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.